Related Experiment Video

Updated: Sep 27, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells

Leslie C Hodges1, Jennifer D Cook, Edward K Lobenhofer

  • 1Department of Carcinogenesis, UT M.D. Anderson Cancer Center, Smithville, TX 78957, USA.

Molecular Cancer Research : MCR
|March 4, 2003
PubMed

Insights

Tamoxifen acts as an estrogen agonist at the molecular level, inducing cell cycle-promoting genes in breast cancer cells. This contrasts with its cellular antagonist function and differs from raloxifene

Area of Science:

  • Molecular Biology
  • Genomics
  • Cancer Research

Background:

  • Tamoxifen is a key therapeutic and preventative agent for breast cancer.
  • While acting as an estrogen antagonist at the cellular level, its molecular actions require further elucidation.

Purpose of the Study:

  • To investigate the molecular mechanisms of tamoxifen action in breast cancer cells.
  • To compare the transcriptional effects of tamoxifen with estrogen and raloxifene.

Main Methods:

  • Transcriptional profiling of breast cancer cells treated with tamoxifen, estrogen, and raloxifene.
  • Analysis of gene expression patterns, focusing on cell cycle-associated genes.

Main Results:

  • Tamoxifen recapitulates estrogen's gene expression profile at the molecular level, acting as an agonist.
  • Tamoxifen induces cell cycle progression genes (e.g., fos, myc, cyclins E/A2) similarly to estrogen, despite cells not cycling.
  • Raloxifene did not induce these specific cell cycle genes; cyclin D1 was notably absent in tamoxifen/raloxifene response but present in resistant cells.

Conclusions:

  • Tamoxifen's molecular action as an estrogen agonist drives specific gene expression changes in breast cancer.
  • Understanding these tamoxifen-induced pathways is crucial for breast cancer therapy and resistance mechanisms.
  • Differential gene expression patterns highlight distinct actions of tamoxifen and raloxifene, with implications for tamoxifen resistance.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...